Scynexis, Inc.

Merck Sharp + Dohme Corp.

Glaxo Group Limited

Aerie Pharmaceuticals, Inc.

Msd K.k.

Sentry Therapeutics Limited

Cypralis Limited

Michael Robert Peel

Weiming Fan

Ahmed Mamai

James M Balkovec

Frances A Bouffard

Andrew Scribner

Keqiang Li

Hao Liu

Mitchell Anthony deLong

Allen E Eckhardt

Mark L Greenlee

Phieng Siliphaivanh

Toshihiro Sakamoto

Dongfang Meng

Tony Siu

Thomas E Richardson

Yoshio Ogino

James Francis Dropinski

David Kendall Jung

Nobuhiko Kawanishi

Cyprian Okwara Ogbu

Brian H Heasley

Marcos Sznaidman

Bruno Tse

Robert H Oakley

Ian Robert Baldwin

David Renwick Houck

Michael James Malaska

Stuart George Cockerill

Bharathi Pandi

Stephen Sean Flack

Jennifer Gabriel Badiang

Matthew G Jenks

Yu Onozaki

Jeffrey David Yingling

Christine Hudson

Kirk Stevens

Koichi Watashi

Satomi Shimura

James Marvin Veal

Thomas F N Haxell

Mui Cheung

Philip Anthony Harris

Shuliang Lee

Joseph A Moore, Iii

Roland A Bouffard, Legal Representative

Sarah Dimick Gray

Keqaing Li

Claire Louise Murray

Byappanahally N Narasinga Rao

Paresma R Patel

Michael John Alberti

Sarah M Dimick Gray

Frances Aileen Bouffard

Joseph A Iii Moore

Jeffrey D Yingling

Andrew William Scribner

Kequiang Li

Marcos L Sznaidman

Mitchell A Delong

The invention relates to cyclic compounds of general formula (I): wherein R, Rand Rare as defined in the specification, and their use as pharmaceuticals. 

Macrocycles

Disclosed are cyclosporine derivatives in which the 3-Sarcosine carbon and 5-Valine nitrogen are each substituted by a non-hydrogen substituent, and their use as pharmaceuticals, in particular for the treatment of hepatitis C virus.

Macrocyclic peptides

The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Inhibitors of Akt activity

Disclosed herein are compounds of general formula (I): wherein A, B, Rand Rare as defined in the specification, and their use as pharmaceuticals.

Novel derivatives of enfumafungin are disclosed herein, along with their, pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (1,3)-&#x3b2;-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

Antifungal agents

The present invention relates to novel enfumafungin derivatives of formula I and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitors of (1,3)-&#x3b2;-D-glucan synthase. The present compounds and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the present compounds and pharmaceutically acceptable salts thereof, are useful for treating or preventing antifungal infections and associated diseases and conditions.

Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

Isoquinoline compounds

Compounds of Formula (I): salts or solvates or physiologically functional derivatives thereof, wherein Z is CH or N, and R, R, and Rare various substituent groups, are protein kinase inhibitors 

Fused pyrazole derivatives being protein kinase inhibitors

Growing community of inventors

Research Triangle Park, NC, United States of America

Michael Robert Peel